logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-6. HCV antibody prevalence among injecting drug users - studies with national and subnational coverage

Part (ii) Young injecting drug users (under age 25), 2009 to 2010

 
 

Notes:

Black squares are samples with national coverage; blue triangles are samples with subnational (including local or regional) coverage. Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary. Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

Source:

Reitox network.

Country Czech Republic Malta Slovenia Hungary Slovakia Austria United Kingdom Poland Belgium Sweden Finland Greece Cyprus Portugal Bulgaria Romania
National 10.7 13.0 13.2 17.5   19.2           52.4 56.3 57.1    
National           36.1           38.7        
Subnational       1.2 22.2 66.7 26.0 54.5 71.4 41.2 44.6 40.0     65.7 82.7
Subnational       40.7   55.0 25.4 17.6 8.3     52.4        
Subnational       47.7   36.6 25.3         41.3        
Subnational       28.6     13         20.0        
Subnational       16.4     76.9         70.0        

inffig6b

 

Page last updated: Friday, 20 July 2012